Core Insights - Jushi Holdings Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -33.33% [1] - The company generated revenues of $68.34 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.39% and showing an increase from $65.86 million year-over-year [2] - Jushi Holdings has not surpassed consensus EPS estimates in the last four quarters, and its shares have declined approximately 31.3% year-to-date compared to a 7.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $67.55 million, while for the current fiscal year, the estimate is -$0.20 on revenues of $299.6 million [7] - The estimate revisions trend for Jushi Holdings was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Jushi Holdings belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

分组1 - Rockwell Medical reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.04, compared to a loss of $0.02 per share a year ago [1][2] - The company's revenues for the quarter were $18.35 million, missing the Zacks Consensus Estimate by 1.16%, and down from $24.67 million year-over-year [3] - Rockwell Medical has not surpassed consensus EPS estimates in the last four quarters, with a recent earnings surprise of -125.00% [2][3] 分组2 - The stock has increased approximately 24.8% since the beginning of the year, while the S&P 500 has declined by 3.7% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $18.7 million, and -$0.03 on revenues of $76.1 million for the current fiscal year [8] - The Zacks Industry Rank for Medical - Products is in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [9]

Core Viewpoint - Neogen (NEOG) is anticipated to report a year-over-year decline in earnings due to lower revenues, with the consensus outlook indicating potential impacts on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on October 9, with a consensus EPS estimate of $0.05 per share, reflecting a year-over-year decrease of 28.6% [3][12]. - Revenues are projected to be $203.18 million, down 6.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 12.5% over the last 30 days, indicating a reassessment by analysts [4]. - Neogen's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - Neogen currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Neogen was expected to post earnings of $0.08 per share but only achieved $0.05, resulting in a surprise of -37.50% [13]. - The company has not beaten consensus EPS estimates in any of the last four quarters [14]. Conclusion - Neogen does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [17].